Guggenheim analyst Michael Schmidt downgraded Fate Therapeutics to Neutral from Buy.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FATE:
- What’s In Store for Fate Therapeutics Heading into 2023?
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Fate Therapeutics downgraded to Perform from Outperform at Oppenheimer
- Fate Therapeutics initiated with a Sell at Goldman Sachs
- Cantor biotech/biopharma analysts hold an analyst/industry conference call